{"id":"https://openalex.org/W2000769256","doi":"https://doi.org/10.1016/j.eurpsy.2006.03.004","title":"Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial","display_name":"Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial","alternate_titles":[],"publication_year":2006,"publication_date":"2006-09-01","ids":{"openalex":"https://openalex.org/W2000769256","doi":"https://doi.org/10.1016/j.eurpsy.2006.03.004","mag":"2000769256","pmid":"https://pubmed.ncbi.nlm.nih.gov/16697153"},"language":"en","primary_location":{"id":"doi:10.1016/j.eurpsy.2006.03.004","doi":"https://doi.org/10.1016/j.eurpsy.2006.03.004","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.eurpsy.2006.03.004","pdf_url":null,"source":{"id":"https://openalex.org/S87202501","display_name":"European Psychiatry","issn_l":"0924-9338","issn":["0924-9338","1778-3585"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Psychiatry","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2000769256"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5072766487","display_name":"Perahia David","orcid":"https://orcid.org/0000-0001-7480-3349","observed_orcids":["https://orcid.org/0000-0001-7480-3349"]},"institutions":[{"id":"https://openalex.org/I4210111545","display_name":"The Gordon Hospital","ror":"https://ror.org/0200b5370","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I21862455","https://openalex.org/I4210111545"]}],"countries":["GB"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"D.G.S. Perahia","raw_affiliation_strings":["Lilly Research Center, Erl Wood, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK. d.perahia@lilly.com","Lilly Research Center, Erl Wood, Sunninghill Road, Windlesham, SurreyGU20 6PH, UK","The Gordon Hospital, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Center, Erl Wood, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK. d.perahia@lilly.com","institution_ids":[]},{"raw_affiliation_string":"Lilly Research Center, Erl Wood, Sunninghill Road, Windlesham, SurreyGU20 6PH, UK","institution_ids":[]},{"raw_affiliation_string":"The Gordon Hospital, London, UK","institution_ids":["https://openalex.org/I4210111545"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090576571","display_name":"F. Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"F. Wang","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042304299","display_name":"Craig H. Mallinckrodt","orcid":"https://orcid.org/0000-0002-8462-6320","observed_orcids":["https://orcid.org/0000-0002-8462-6320"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"C.H. Mallinckrodt","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102916328","display_name":"Daniel J. Walker","orcid":"https://orcid.org/0000-0002-9369-6953","observed_orcids":["https://orcid.org/0000-0002-9369-6953"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"D.J. Walker","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113644572","display_name":"Michael J. Detke","orcid":"https://orcid.org/0000-0002-2195-8651","observed_orcids":["https://orcid.org/0000-0002-2195-8651"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I4394709130","display_name":"Indiana University School of Medicine","ror":"https://ror.org/02ets8c94","country_code":"US","type":"education","lineage":["https://openalex.org/I4394709130","https://openalex.org/I592451"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M.J. Detke","raw_affiliation_strings":["Harvard Medical School, Boston, MA, USA","Indiana University School of Medicine, Indianapolis, IN, USA","Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Indiana University School of Medicine, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I4394709130"]},{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5072766487"],"corresponding_institution_ids":["https://openalex.org/I4210111545"],"apc_list":{"value":3300,"currency":"USD","value_usd":3300},"apc_paid":null,"fwci":7.1029,"has_fulltext":false,"cited_by_count":135,"citation_normalized_percentile":{"value":0.97666034,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"21","issue":"6","first_page":"367","last_page":"378"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10853","display_name":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T13118","display_name":"Psychological Treatments and Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/duloxetine","display_name":"duloxetine","score":0.996999979019165},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.9980000257492065},{"id":"https://openalex.org/keywords/paroxetine","display_name":"paroxetine","score":0.9390000104904175},{"id":"https://openalex.org/keywords/antidepressant-efficacy","display_name":"antidepressant efficacy","score":0.8220000267028809},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.8100000023841858},{"id":"https://openalex.org/keywords/sexual-dysfunction","display_name":"sexual dysfunction","score":0.7440000176429749},{"id":"https://openalex.org/keywords/non-inferiority","display_name":"non-inferiority","score":0.8460000157356262},{"id":"https://openalex.org/keywords/continuation-therapy","display_name":"continuation treatment","score":0.5989999771118164},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.5879999995231628},{"id":"https://openalex.org/keywords/hamilton-depression-rating-scale","display_name":"Hamilton Depression Rating Scale","score":0.6449999809265137},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.7170000076293945},{"id":"https://openalex.org/keywords/weight-change","display_name":"weight change","score":0.31700000166893005},{"id":"https://openalex.org/keywords/vital-signs","display_name":"vital signs","score":0.6850000023841858}],"concepts":[{"id":"https://openalex.org/C2780764818","wikidata":"https://www.wikidata.org/wiki/Q411932","display_name":"Duloxetine","level":3,"score":0.9566601514816284},{"id":"https://openalex.org/C2777828372","wikidata":"https://www.wikidata.org/wiki/Q408471","display_name":"Paroxetine","level":4,"score":0.9239210486412048},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.674648642539978},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.5667930841445923},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.5253433585166931},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.43615198135375977},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4329095482826233},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.15615689754486084},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.11291742324829102},{"id":"https://openalex.org/C2780733359","wikidata":"https://www.wikidata.org/wiki/Q331769","display_name":"Mood","level":2,"score":0.10649031400680542},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.037541478872299194},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068736","descriptor_name":"Duloxetine Hydrochloride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008403","descriptor_name":"Mass Screening","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012074","descriptor_name":"Remission Induction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013876","descriptor_name":"Thiophenes","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013876","descriptor_name":"Thiophenes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015990","descriptor_name":"Placebo Effect","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015995","descriptor_name":"Prevalence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D017374","descriptor_name":"Paroxetine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.eurpsy.2006.03.004","doi":"https://doi.org/10.1016/j.eurpsy.2006.03.004","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.eurpsy.2006.03.004","pdf_url":null,"source":{"id":"https://openalex.org/S87202501","display_name":"European Psychiatry","issn_l":"0924-9338","issn":["0924-9338","1778-3585"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Psychiatry","raw_type":"journal-article"},{"id":"pmid:16697153","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16697153","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European psychiatry : the journal of the Association of European Psychiatrists","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":32,"referenced_works":["https://openalex.org/W72273208","https://openalex.org/W1634744991","https://openalex.org/W1688398500","https://openalex.org/W1971393265","https://openalex.org/W1972965892","https://openalex.org/W1974128420","https://openalex.org/W1982721912","https://openalex.org/W1990161259","https://openalex.org/W1993810702","https://openalex.org/W1995051494","https://openalex.org/W2003363634","https://openalex.org/W2025218217","https://openalex.org/W2047902057","https://openalex.org/W2054061970","https://openalex.org/W2068124573","https://openalex.org/W2069090735","https://openalex.org/W2070468494","https://openalex.org/W2073155558","https://openalex.org/W2075555377","https://openalex.org/W2076992585","https://openalex.org/W2089659183","https://openalex.org/W2114613490","https://openalex.org/W2131823335","https://openalex.org/W2145158233","https://openalex.org/W2147464017","https://openalex.org/W2160070901","https://openalex.org/W2164182651","https://openalex.org/W2235189311","https://openalex.org/W2407635962","https://openalex.org/W3171418018","https://openalex.org/W6602900257","https://openalex.org/W7074234824"],"related_works":["https://openalex.org/W2047902057","https://openalex.org/W1982721912","https://openalex.org/W2098354008","https://openalex.org/W2003363634","https://openalex.org/W2373004272","https://openalex.org/W2159484656","https://openalex.org/W1978588976","https://openalex.org/W1971663696","https://openalex.org/W1963482722","https://openalex.org/W1971393265"],"abstract_inverted_index":{"OBJECTIVE:":[0],"Duloxetine":[1,218],"doses":[2,287,320],"of":[3,17,79,83,99,137,174,231,241,246,278,317,321,329,357],"80":[4,44,238,322],"and":[5,12,91,97,106,162,243,264,304,323,338,346],"120":[6,48,219,324],"mg/day":[7,45,49,54,220,239,325,345],"were":[8,38,88,93,165,248,269,298,340],"assessed":[9,94,166],"for":[10,36,71,275,291],"efficacy":[11,85,161,228,316],"safety":[13,339],"in":[14,65,129,180,193,300,308,326,354],"the":[15,66,130,135,138,150,158,177,194,216,276,309,327,355],"treatment":[16,152,182,302,328,356],"major":[18],"depressive":[19],"disorder":[20],"(MDD).":[21],"METHODS:":[22],"In":[23],"this":[24,262],"randomized,":[25],"double-blind":[26],"trial,":[27],"patients":[28,175,185],"age":[29],">":[30,123],"or":[31,51,124,311],"=18":[32],"meeting":[33],"DSM-IV":[34],"criteria":[35,290],"MDD":[37,330],"randomized":[39],"to":[40,115,251,293,342],"placebo":[41,210,235,252],"(N=99),":[42],"duloxetine":[43,47,237,286,318,353],"(N=93),":[46],"(N=103),":[50],"paroxetine":[52,244,343],"20":[53,344],"(N=97).":[55],"The":[56,108,315],"primary":[57],"outcome":[58],"measure":[59],"was":[60,113,205,331],"mean":[61,213,258],"change":[62,214,259],"from":[63,127,209,261],"baseline":[64,128],"17-item":[67],"Hamilton":[68],"rating":[69],"scale":[70,112],"depression":[72],"(HAMD(17))":[73],"total":[74,132,196],"score":[75,133,197],"after":[76],"8":[77,200],"weeks":[78],"treatment;":[80],"a":[81,122,142,273,280],"number":[82],"secondary":[84,227,255],"measures":[86,229],"also":[87,221],"assessed.":[89],"Safety":[90],"tolerability":[92],"via":[95],"collection":[96],"analysis":[98],"treatment-emergent":[100],"adverse":[101],"events":[102],"(TEAEs),":[103],"vital":[104],"signs,":[105],"weight.":[107],"Arizona":[109],"sexual":[110,117],"experiences":[111],"used":[114],"assess":[116],"functioning.":[118],"Patients":[119],"who":[120],"had":[121,155],"=30%":[125],"reduction":[126],"HAMD(17)":[131,195,257],"at":[134,198,319],"end":[136],"acute":[139,159,178,310],"phase":[140,145,179],"entered":[141],"6-month":[143],"continuation":[144,168,312],"where":[146],"they":[147,154],"remained":[148],"on":[149,212,215,225,253,352],"same":[151],"as":[153,271,334],"taken":[156],"during":[157,167],"phase;":[160],"safety/tolerability":[163],"outcomes":[164],"treatment.":[169],"RESULTS:":[170],"More":[171],"than":[172],"87%":[173],"completed":[176],"each":[181],"group.":[183],"Duloxetine-treated":[184],"(both":[186],"doses)":[187],"showed":[188,222],"significantly":[189,207,249],"greater":[190],"improvement":[191,224],"(P<0.05)":[192],"week":[199],"compared":[201,233],"with":[202,234,348],"placebo.":[203],"Paroxetine":[204],"not":[206],"different":[208],"(P=0.089)":[211],"HAMD(17).":[217],"significant":[223],"most":[226],"(six":[230],"nine)":[232,242,247],"while":[236],"(three":[240,245],"superior":[250],"fewer":[254],"measures.":[256],"data":[260,351],"study":[263,268],"an":[265],"identical":[266],"sister":[267],"pooled":[270],"defined":[272],"priori":[274],"purposes":[277],"performing":[279],"non-inferiority":[281,292],"test":[282],"versus":[283],"paroxetine.":[284,294],"Both":[285],"met":[288],"statistical":[289],"TEAE":[295],"reporting":[296],"rates":[297],"low":[299],"all":[301],"groups":[303],"no":[305],"deaths":[306],"occurred":[307],"phases.":[313],"CONCLUSIONS:":[314],"demonstrated.":[332],"Tolerability,":[333],"measured":[335],"by":[336],"TEAEs,":[337],"similar":[341],"consistent":[347],"previous":[349],"published":[350],"MDD.":[358]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2000769256","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":8}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
